| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.16 | 3e-06 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0004 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.19 | 0.001 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.003 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.54 | 0.004 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.004 |